Subscribe: Market Wire - Pharmaceuticals and Biotech: Drugs
http://img.marketwire.com/rss/mwPBDR.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announced  clinical stage  clinical  common stock  company  december  drug  marketwired december  marketwired  patent  stock  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Drugs

Marketwired - Drugs



Marketwired - Drugs



Last Build Date: Mon, 11 Dec 2017 09:56:22 EST

Copyright: Copyright: (C) Marketwired
 



VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock

Mon, 11 Dec 2017 09:25:18 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - December 11, 2017) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN) ("VistaGen" or the "Company"), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system disorders, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and warrants to purchase up to 10,000,000 shares of common stock at an offering price of $1.50 per share and related warrant. Each share of common stock is being sold together with a warrant to purchase one share of common stock. The warrants are immediately exercisable, have an exercise price of $1.50 per share and will terminate 5 years from the date of issuance. The gross proceeds of the offering are expected to be approximately $15 million, before deducting the underwriting discount and other estimated offering expenses.




Rennova Health Announces an Upgrade of MedicalMime's Flagship EHR M2Select to Version 3.3

Mon, 11 Dec 2017 09:20:00 EST

WEST PALM BEACH, FL--(Marketwired - December 11, 2017) - Rennova Health, Inc. (OTCQB: RNVA) (OTCQB: RNVAW) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers that opened its first rural hospital in Oneida, Tenn. on August 8, 2017, announces an upgrade of its flagship electronic health records (EHR) platform, M2Select to Version 3.3. This platform is available to office-based physicians, as well as to mental health providers working in substance abuse and drug and alcohol rehabilitation facilities.




Rising Overdose Deaths in Orange County Prompt New Addiction Treatment Center to Open

Mon, 11 Dec 2017 09:00:00 EST

CleanSlate Combating Tragic Rates of Opioid Dependency in Infants by Increasing Access to Treatment, Fast-Tracking Expectant Moms




Strength Sensei Nutraceuticals et Charles R. Poliquin lancent MaxSimil®

Mon, 11 Dec 2017 08:30:00 EST

LAVAL, QUÉBEC--(Marketwired - 11 déc. 2017) - Neptune Technologies & Bioressources inc. (« Neptune » ou la « Société ») (NASDAQ:NEPT)(TSX:NEPT) annonce, en partenariat avec Strength Sensei Nutraceuticals, une entreprise de Charles R. Poliquin, le lancement d'Omega DriveMC, un produit contenant de l'AEP et de l'ADH, deux acides gras oméga-3, et qui, enrichi de MaxSimil®, se destine au milieu de la préparation physique.




Strength Sensei Nutraceuticals and Charles R. Poliquin launch MaxSimil®

Mon, 11 Dec 2017 08:30:00 EST

LAVAL, QUÉBEC--(Marketwired - Dec. 11, 2017) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NEPT) announces, in partnership with Charles R. Poliquin's Strength Sensei Nutraceuticals, the launch of MaxSimil® enhanced Omega DriveT omega-3 EPA and DHA product for the strength coaching community.




Trillium Therapeutics Provides Update on its TTI-621 Program at the American Society of Hematology 59th Annual Meeting

Mon, 11 Dec 2017 08:00:00 EST

- Locoregional Tumor Regression Frequently Observed in CTCL Patients Receiving Intratumoral TTI-621 Monotherapy

- Heavily Pre-treated Patients with Relapsed/Refractory DLBCL Can Achieve Objective Responses and/or Prolonged Progression-Free Intervals, Particularly when Treated in Combination with Rituximab

- Growing Safety Database Shows TTI-621 to be Well Tolerated




IntelGenx Receives USPTO Notice of Allowance for Montelukast Orange Book Eligible Patent

Mon, 11 Dec 2017 08:00:00 EST

SAINT-LAURENT, QUEBEC--(Marketwired - Dec. 11, 2017) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) ("IntelGenx"), a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilmT technology platform, today announced that the United States Patent and Trademark Office ("USPTO") has granted a Notice of Allowance for US Patent Application 15/299,054, entitled "Device and Method of Treating Conditions Associated with Neuroinflammation." This film formulation patent covers Montelukast oral film formulations designed for the treatment of neuroinflammation and is intended to protect IntelGenx' Montelukast VersaFilmT product.




BioVie Receives FDA Fast Track Designation for BIV201 for the Treatment of Refractory Ascites Due to Advanced Liver Cirrhosis

Mon, 11 Dec 2017 07:00:00 EST

BEVERLY, MA--(Marketwired - December 11, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for BIV201 (continuous infusion terlipressin), the Company's patented Orphan drug candidate. BIV201 is currently being evaluated for the treatment of refractory ascites due to liver cirrhosis in a mid-stage (Phase 2a) US clinical trial, with 2 of the planned 6 patients having been treated with this therapy to date.




Tetra Bio-Pharma provides update on status of its Phase 3 Clinical Trial Application of Lead Drug Candidate PPP001

Sat, 09 Dec 2017 12:00:00 EST

OTTAWA, ONTARIO--(Marketwired - Dec. 9, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process. As such, the quality certification for the manufacturing of PPP001 will take place prior to the approval of its clinical trial protocol as Health Canada assesses its partner Aphria's operations for Good Manufacturing Practices (GMP) for pharmaceutical products. Tetra agrees to this change from Health Canada because it is in the best interest of patients.




Aequus announces the issuance of stock options

Fri, 08 Dec 2017 20:04:14 EST

VANCOUVER, BC--(Marketwired - December 08, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the issuance of stock options to directors, officers, staff and consultants. The stock options give the holders the right to purchase up to an aggregate of 2,302,941 common shares of the Company. These stock options are exercisable at a price of $0.195 per share, for a term of eight years, and vest in tranches over 2 to 3 year periods. The terms of the stock options granted on December 7, 2017 are in accordance with the Company's Stock Option Plan.




VistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent on Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer

Fri, 08 Dec 2017 09:00:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - December 08, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,834,754 related to methods for producing, from human pluripotent stem cells (hPSCs), hematopoietic precursor stem cells, which are stem cells that give rise to all of the blood cells and most of the bone marrow cells in the body. VistaGen holds an exclusive license to this patent from the University Health Network (UHN).




ANGLE plc Announces Parsortix Potential in Metastatic Breast Cancer

Fri, 08 Dec 2017 02:00:00 EST

GUILDFORD, SURREY--(Marketwired - Dec 8, 2017) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)




ViaDerma, Inc. Looks to have Sales Representatives Selling its FDA Registered Medication VitaStem to a Network of 1000 Physician Offices Nationwide in 2018

Thu, 07 Dec 2017 08:42:32 EST

LOS ANGELES, CA--(Marketwired - December 07, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has begun sales and distribution of its highly anticipated topical antibiotic ointment Vitastem. ViaDerma will work with a new sales and marketing group to put 25 sales representatives on the ground selling ViaDerma's products to networks of Hospitals and directly to physicians' offices. The projected revenues for 2018 from this initiative should generate $6.9 million dollars.




Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402

Thu, 07 Dec 2017 08:30:00 EST

BOSTON, MA--(Marketwired - December 07, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it has received approval from the Human Research Ethics Committee and authority from the Therapeutic Goods Administration to initiate its first-in-human study in Australia for PRS-060/AZD1402, an inhaled Anticalin protein that targets IL-4R? for the treatment of moderate to severe asthmatic patients that are not controlled on standard of care. This phase 1 study will be conducted in healthy subjects and is being developed as part of Pieris' strategic alliance with AstraZeneca, which is funding the trial, with Pieris being responsible for conducting the study.




Critical Outcome Technologies Annual and Special Meeting of Shareholders Rescheduled

Wed, 06 Dec 2017 17:45:35 EST

LONDON, ONTARIO and BOSTON, MASSACHUSETTS--(Marketwired - Dec. 6, 2017) - Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced a change in the previously set date for the Company's Annual and Special Meeting of Shareholders (the "Meeting"), which was originally scheduled for Thursday, December 7, 2017 at 9:30 a.m. Eastern Standard Time.




Tetra Bio-Pharma Opens Markets at TSX Listing Ceremony

Wed, 06 Dec 2017 14:01:19 EST

Clarification on PR issued on November 28th 2017




Moleculin's WP1066 Drug receives $2 million Private Grant

Wed, 06 Dec 2017 10:01:00 EST

HOUSTON, TX--(Marketwired - December 06, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), announced that its WP1066 drug will receive $2 million in private grant funding for its recently announced Investigational New Drug ("IND") clearance for a physician-sponsored Phase I trial of Moleculin's drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma.




VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101

Wed, 06 Dec 2017 09:08:09 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - December 06, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,834,801 related to certain methods of production for AV-101, VistaGen's lead CNS product candidate.




Vernalis and Servier Achieve Research Milestone

Wed, 06 Dec 2017 02:00:00 EST

WINNERSH, UNITED KINGDOM--(Marketwired - Dec 6, 2017) - Vernalis PLC (LSE: VER)




Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tue, 05 Dec 2017 16:01:00 EST

BERKELEY, CA--(Marketwired - December 05, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on November 28, 2017 the Compensation Committee of Dynavax's Board of Directors approved (i) the grant of inducement stock options to purchase an aggregate 73,800 shares of common stock and (ii) an inducement restricted stock unit award covering an aggregate of 1,000 shares of common stock, to six new employees. These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).




NutraFuels, Inc. (NTFU) Provides 3rd Quarter Financials

Tue, 05 Dec 2017 10:27:43 EST

COCONUT CREEK, FL--(Marketwired - December 05, 2017) - NutraFuels Inc. ("NutraFuels" or "NTFU"), (OTC PINK: NTFU), today announced financial results for its fiscal 2017 third quarter ended September 30th, 2017. The Company posted quarterly revenue of $652,329 and quarterly loss per diluted share of $(0.0008). These results compare to revenue of $44,208 and loss per diluted share of $($0.014) in the same quarter of last year.




IntelGenx to Regain Exclusive Worldwide Rights to Develop and Commercialize RIZAPORT(R)

Tue, 05 Dec 2017 09:30:00 EST

FDA Requests More Information Before Full Review of RIZAPORT(R) NDA Resubmission




Vaxil Strengthens Board of Directors and Management Concurrent to $1-Million Financing

Tue, 05 Dec 2017 08:30:00 EST

NESS-ZIONA, ISRAEL--(Marketwired - December 05, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli immuno-oncology biotechnology company, is pleased to announce the addition of two veteran healthcare executives to its Board of Directors. Dr. Ari Kellen, formerly of McKinsey & Company, Bausch + Lomb, and Valeant; together with Dr. Shawn Langer, formerly of McKinsey & Company, and a current healthcare private equity portfolio manager with BMHS Investments, have joined Vaxil's Board of Directors. Director Mr. Isaac Maresky, an investment banking professional with hundreds of millions of dollars of financings and M&A experience, including co-founding another successful immunotherapy company, has been appointed CEO of Vaxil.




Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance

Tue, 05 Dec 2017 07:00:00 EST

HOUSTON, TX--(Marketwired - December 05, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), announced the physician-sponsored Investigational New Drug ("IND") application for a Phase I trial of Moleculin's drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma has been allowed by the US Food and Drug Administration ("FDA").